Studies show that patients who are obese or overweight using injectable GLP-1 agonist medications for weight loss, combined with diet and exercise, achieve weight loss of approximately 6% of their body weight at 4 months, 9% at 6 months, and 13% at 12 months
PlexusDx compounds semaglutide from licensed 503A pharmacies, allowing precise dose customization to minimize side effects
GLP-1 Agonist Medications Targeting GLP-1 has become a primary area of focus for cardiometabolic health, including weight management
GHK-Cu promotes fibroblast proliferation, collagen synthesis, angiogenesis, and ECM remodeling, while KPV, including advanced formulations such as KPV@PPP_E, exerts anti-inflammatory effects and supports tissue repair
F.Prez-FernandezL.Cuevas-SchachtF.Valencia-MaquedaE.TernL